FASN and neoplasm: Inhibitors targeting lipogenic enzymes regulated by SREBF1, such as FASN and ACSLs, have been investigated in preclinical trials and evaluated for tumor growth, angiogenesis, and metastasis incidence in mouse carcinogenesis models; however, problematic side effects occurred.[35] The SREBF1 inhibitors fatostatin and betulin suppressed tumor growth and activity in previous studies.[36] Herein, fatostatin showed significant suppressive effects on tumor growth in PCa, with higher expression levels of BHLHE40 (Figure 7E–I).